本文源自：金融界AI电报 据英国金融时报：SpaceX权衡在6月IPO，公司正寻求以约1.5万亿美元的估值筹集高达500亿美元。 ...

据港交所文件，1月23日，浙江迦智科技股份有限公司向港交所递交上市申请书，中金公司为独家保荐 人。据迦智科技披露，于2026年1月，公司完成C++轮融资人民币1.8亿元。 | 纂]項下的[编纂]數目 | .. | [编纂]股H股(視乎[编纂]行使奥否而定) | | --- | --- | --- | | [编纂]數目 | .. | [编纂]股H股(可于[编纂]) | | [编纂]數目 | .. | [编纂]股日股(可于[编纂]及視乎[编纂]行使與否而 | | | | 定) | | 最高[编纂] | : | 每股H股[编纂]港元,另加1.0%經紀佣金、 | | | | 0.00015%會財局交易微費、0.0027%證監會交 | | | | 易微費及0.00565%聯交所交易費(須於[編纂]時 | | | | 以港元繳足,多繳款項可予退還) | | 面值 | a a | 每股H股人民幣1.00元 | | [编纂] | : [编纂] | | ...

（编辑 王雪儿） 证券日报网讯 1月23日，三峡能源在互动平台回答投资者提问时表示，上市是公司发展的重要里程碑， 为公司未来经营发展提供资金，并帮助公司增强投资能力，推动管理水平提升，增强核心竞争力，加速 治理体系和治理能力现代化建设。 ...

《星岛》记者 秦亦 深圳报道 近期，创尔生物（NQ:831187）发布公告，宣布终止北交所上市辅导备案，意味着该公司推进三年之久 的IPO之路正式折戟，一场筹备已久的资本市场冲刺最终未能如愿。 ▲创尔生物终止上市辅导。 创尔生物主要产品为医疗器械类和生物护肤类，在医疗器械方面，该公司已掌握生物医用级活性胶原大 规模无菌提取制备技术，拥有2个Ⅲ类及2个Ⅱ类医疗器械注册证。2017-2019年，公司胶原类产品在我 国医药级胶原市场的市场份额分别为3.04%、3.40%和5.23%。 创尔生物并未在公告中披露股东股权冻结的细节，但据《星岛》了解，这与其二股东丁玉梅有直接关 联。根据创尔生物2025年半年报显示，丁玉梅持有该公司365.36万股，持股比例4.30%，成为第二大股 东。不过，这部分股权已悉数被司法冻结，无任何可流通空间。 事实上，创尔生物的上市之路并非一帆风顺，2020年该公司曾冲击科创板，2021年撤回上市申请材料后 转向北交所，如今却因一桩股权隐患再度停摆。 | | | | | | | | | 期末 | 单位:股 | | --- | --- | --- | --- | --- | --- | --- ...

0:00 据报道，马斯克正积极推进SpaceX的上市计划，其目标是在今年7月前完成IPO。 ...

Core Viewpoint - The company, Jiangsu Xinquan Automotive Trim Co., Ltd., held its first extraordinary general meeting of shareholders in 2026, where several key resolutions were passed, including the issuance of H-shares and listing on the Hong Kong Stock Exchange [2][4][9]. Meeting Details - The meeting was held on January 21, 2026, at the company's Changzhou branch [2]. - The meeting was convened by the board of directors and chaired by the chairman, utilizing a combination of on-site and online voting methods [2][3]. Attendance - All 9 current directors attended the meeting, along with the company secretary and senior management [3][4]. Resolutions Passed - The following key resolutions were approved: - Issuance of H-shares and listing on the Hong Kong Stock Exchange [4]. - Various aspects of the H-share issuance, including types and par value, issuance and listing timeline, issuance method, scale, pricing method, and underwriting method [4][5][6]. - Approval of the fundraising plan related to the H-share issuance [6]. - Appointment of audit firms for the H-share issuance and listing [6]. - Election of independent directors and determination of their remuneration [7]. - Amendments to the company's articles of association [7]. - Authorization for the board to handle matters related to the H-share issuance [7]. - Approval of insurance for directors and senior management [7][10]. Legal Verification - The meeting was witnessed by Shanghai Jintiancheng Law Firm, confirming that the procedures and resolutions complied with relevant laws and regulations [11].

天华新能（300390）(300390.SZ)公告，公司正在筹划在境外发行股份(H股)并在中国香港联合交易所有 限公司上市。截至本公告披露日，公司正在与相关中介机构就本次H股发行上市的具体推进工作进行商 讨，相关细节尚未确定。本次发行H股并上市不会导致公司控股股东和实际控制人发生变化。 ...

据港交所文件，1月20日，深圳市沃客非凡科技股份有限公司向港交所提交上市申请书，独家保荐人为 华泰国际。 | 酸上即是差颜目 | .. | [编纂]股H股(税平[编纂]行使與否而定) | | --- | --- | --- | | [编纂]數目 | .. | [编纂]股H股(可予重新分配) | | [编纂]數目 | .. | [编纂]股H股(可于重新分配及視乎[编纂]行使與否 | | 而定) | | | | 最高[编纂] : 每股H股[编纂]港元,另加1.0％經紀佣金、0.0027％ | | | | 設監育交易微費、0.00565%香港輪交所交易費 | | | | 及0.00015%有財局交易微費(須於申請時以港元 | | | | 繳足,多繳股款可予退還) | | | | 面值 | ิ | 每股田股人民幣[0.1]元 | | [编纂] : [编纂] | | | | 獨家保應人,[編纂] | | | | 1 4 = = D = | | | ...

Group 1 - The company plans to globally offer 14.1011 million shares, with 1.4102 million shares available in Hong Kong and 12.6909 million shares for international sale, along with an over-allotment option of 2.1151 million shares [1] - The subscription period is set from January 20 to January 23, with a maximum offer price of 236.60 HKD per share, and an entry fee of approximately 23,898.62 HKD for 100 shares [1] - The total expected fundraising amount is 3.287 billion HKD, with a net amount of 3.124 billion HKD, aimed at enhancing supply chain capabilities, product development, technology, digitalization, store network upgrades, brand promotion, and potential strategic investments [1] Group 2 - The company is a mature and steadily developing food and beverage retailer in China [2] - The net profits for the fiscal years 2023, 2024, and the first three quarters of 2025 (ending September 30) are projected to be 217 million, 834 million, and 1.559 billion CNY, reflecting year-on-year growth rates of 203.45%, 283.44%, and 215.91% respectively [2]

Group 1 - The core viewpoint of the article is that Shandong Huawutang Cosmetics Co., Ltd., the parent company of Banmu Huatian, has submitted a listing application to the Hong Kong Stock Exchange with CITIC Securities as the sole sponsor [1] - The company’s adjusted net profit is projected to increase by 249.4% from RMB 23.7 million in 2023 to RMB 82.8 million in 2024 [1] - For the nine months ending September 30, 2024, the adjusted net profit is expected to rise by 197.2% from RMB 49.7 million to RMB 147.7 million in the same period of 2025 [1]